AP&T: CONTENTS LISTING FOR THE 1st JULY 2017 ISSUE

The contents listing for the 1st July 2017 issue of Alimentary Pharmacology & Therapeutics is listed below and, as a member of the New Zealand Society of Gastroenterology, you have free access to all these articles when you log-in via the Members’ Area of the NZSG website - www.nzsg.org.nz

Yours sincerely

Roy

Professor R E Pounder
Co-Editor
Alimentary Pharmacology & Therapeutics
website: www.APandT.org
Follow AP&T on Twitter: @APandT

------------------------------------------------------------------------------------------------------

CONTENTS LIST FOR 1st JULY 2017 ISSUE OF
ALIMENTARY PHARMACOLOGY & THERAPEUTICS


SYSTEMATIC REVIEW

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease (pages 3–15)
W. A. Bye, V. Jairath and S. P. L. Travis


REVIEW ARTICLE

Review article: maximising quality of life while aspiring for quantity of life in end-stage liver disease (pages 16–25)
R. A. Bhanji, E. J. Carey and K. D. Watt


NOVEL SEROLOGICAL MARKER FOR CROHN’S

Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease (pages 26–39)
W. T. van Haaften, J. H. Mortensen, M. A. Karsdal, A. C. Bay-Jensen, G. Dijkstra and P. Olinga


RISK OF CANCER IN GASTRIC INTESTINAL METAPLASIA

The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up (pages 40–45)
R. Pittayanon, R. Rerknimitr, N. Klaikaew, A. Sanpavat, S. Chaithongrat, V. Mahachai, P. Kullavanijaya and A. Barkun


ACUTE KIDNEY INJURY WITH SOFOSBUVIR

The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens (pages 46–55)
R. Maan, S. H. Al Marzooqi, J. S. Klair, J. Karkada, O. Cerocchi, M. Kowgier, S. M. Harrell, K. D. Rhodes, H. L. A. Janssen, J. J. Feld and A. Duarte-Rojo


PIOGLITAZONE IN NASH

Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis (pages 56–61)
M. Kawaguchi-Suzuki, F. Bril, S. Kalavalapalli, K. Cusi and R. F. Frye


INVITED EDITORIALS

Editorial: should we recommend oesophageal biopsies for all patients with symptoms suggestive of GERD? (pages 62–63)
S. Roman and F. Mion

Editorial: the Millennium study cohort―evaluating environmental determinates of IBD in the 21st century (pages 63–64)
G. G. Kaplan

Editorial: the Millennium study cohort―evaluating environmental determinates of IBD in the 21st Century. Authors' reply (pages 64–65)
C. K. Porter, M. S. Riddle and T. I. Hooper

Editorial: non-alcoholic fatty liver disease―a pandemic in need of novel treatments and endpoints (pages 65–66)
V. Ajmera and R. Loomba

Editorial: tacrolimus―how low can you go? (pages 66–68)
J. G. O'Leary

Editorial: biologics in inflammatory bowel disease―time for direct comparisons (pages 68–69)
R. C. Ungaro and J.-F. Colombel

Editorial: developing a stimulation test to identify FGF19 deficiency in bile acid diarrhoea (pages 69–70)
J. R. F. Walters

Editorial: functional dyspepsia―a disorder of duodenal permeability? (pages 70–71)
N. Vakil

Editorial: the diminishing returns of normalisation of the oesophageal mucosa (pages 71–72)
R. M. Genta

Editorial: the diminishing returns of normalisation of the oesophageal mucosa―Authors' reply (pages 73–74)
L. Mastracci, R. Fiocca, C. Engstrom, S. Attwood, C. Ell, J. P. Galmiche, J. G. Hatlebakk, G. Långström, S. Eklund, T. Lind and L. Lundell

Editorial: repeat duodenal biopsy for patients with coeliac disease―physician heal thyself and dietitian heal the patient! (pages 74–75)
N. Trott, M. Kurien and D. S. Sanders


LETTERS TO THE EDITORS

Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation (page 76)
M. S. Rezaee-Zavareh and S. M. Alavian

Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation―Authors' reply (page 77)
A. Andriulli, M. Guarino and F. Morisco

Letter: determining the dominant role of environmental factors in UC development (pages 77–78)
S. Wang and J. Lin

Letter: determining the dominant role of environmental factors in UC development―Authors' reply (pages 78–79)
T. Hammer, S. N. Lophaven, J. Burisch and E. Lynge

Letter: sublingual dosing of tacrolimus in transplant patients―interesting concept to overcome first pass effects (pages 79–80)
N. R. Srinivas

Letter: sublingual dosing of tacrolimus in transplant patients―interesting concept to overcome first pass effects. Authors' reply (page 80)
C. Benítez, J. I. Vargas and S. Solari

Letter: should Barrett's oesophagus be considered a potential cardiovascular risk factor? (pages 80–81)
S. Kilincalp and S. Altiner